


Figure S1

A



B




Figure S1. The absolute levels of studied proteins shown in Figure 1 were normalized to beta-actin (ACTB) and plotted in the graph.



Figure S2**A****B****Figure S2.** The levels of studied proteins in Figure 4 were normalized to ACTB and plotted in the graph. The changes in p53 expression are highlighted in blue.

Figure S3





Figure S3. The levels of studied proteins in Figure 4 were normalized to ACTB and plotted in the graph. The changes in p53 expression are highlighted either in blue to compare the effect of DUSP10 expression within the same cell line or in red for evaluation of p53 levels in relation to AGR2 expression.

Figure S4

A



B




Figure S4. MTT assay. A549 (A) and MCF-7 (B) cells transfected either with control siRNA or siRNA against AGR2 were exposed to cisplatin or doxorubicin for 48 hrs. This experiment was performed in five technical replicates for each treatment.

Figure S5






Figure S5. Colony forming assay. H1299 cells either mock transfected or transfected with p53 or co-transfected with AGR2 and p53 were diluted and seeded into six-well plates and exposed to low doses of cisplatin or doxorubicin. The number of colonies was counted after 14 days. Each combination was analyzed in 6 technical replicates in six well plates.

Figure S6

A



B



C




Figure S6. Cell proliferation and cytotoxicity testing. Proliferation profiles of H1299-LZ4 cells and H1299-LZ4-AGR2 either mock- or p53- transfected. Cells were untreated (A), exposed to cisplatin (B) or doxorubicin (C).

Figure S7




Figure S7. Box/Whisker plot demonstrating sensitivity of *ex vivo* cultured breast cancer cells to doxorubicin with respect to *AGR2* expression.

Figure S8






Figure S8. Overall survival of 115 consecutive breast cancer patients who received anthracyclines in adjuvant treatment with respect to AGR2 IHC staining (A); overall survival in subgroup of breast cancer patients with wt p53 only (B).

Figure S9




	0	50	100	150	200
low	171	135	104	16	0
high	63	42	27	5	2




	0	50	100	150	200
low	152	118	93	14	1
high	82	59	38	7	1

Figure S9. Online survival meta-analysis in cohort of ER-positive, wt p53 breast tumors in relation to *AGR2* (A) and *DUSP10* (B) expression.

Figure S10



	0	50	100	150	200	250
low	1002	545	242	51	7	1
high	2552	1770	828	190	20	2



	0	50	100	150	200	250
low	2360	1558	708	146	13	1
high	1194	757	362	95	14	2

Figure S10. Online survival meta-analysis in whole cohort of breast tumors in relation to *AGR2* (A) and *DUSP10* (B) expression.